Introduction

Professor Julian gilmer discusses a trial of n t l two thousand and one, a new crisper casnine base in beve gen editing therapy for the treatment of patients with hereditary transeratine. Amilo doses with polyneuropathy. This week's feature interview is with doctor whitney fit who focuses on the long term outcome of patients with posmodic imagination.